Alcon AG（ALC）股票分析ALCAlcon AG

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries. It operates in the Healthcare sector.

Alcon AG (ALC) appears to be a good buy at the current price of $66.18, especially considering the recent FDA approval of its BRYTLY eye drops, which could drive future revenue growth. The stock has a forward P/E ratio of 16.23, suggesting it is reasonably valued for growth potential. Additionally, hedge funds have increased their buying activity by 470.50% over the last quarter, indicating strong institutional interest. However, a key risk is the recent drop in net income to zero in Q2 2026, which raises concerns about short-term profitability.